Biomarker-Driven Lung Cancer | Clinical

Study Underway to Test ALRN-6924 in p53-Mutated Non–Small Cell Lung Cancer

July 02, 2021

A phase 1b trial is currently recruiting patients with advanced p53-mutated non­–small cell lung cancer in order to determine the safety and efficacy of ALRN-6924, and reduce chemotherapy toxicity in this patient population.

The Latest Practices for Testing and Treating Lung Adenocarcinoma

June 21, 2021

In an interview with Targeted Oncology, Aaron Lisberg, MD spoke on the importance of molecular testing for patients with lung adenocarcinoma, and provided tips for choosing between immunotherapy and a tyrosine kinase inhibitor.

CLN-081 Demonstrates Anti-Tumor Activity and Safety in EGFR+ NSCLC

June 04, 2021

Patients with previously treated non–small cell lung cancer harboring EGFR exon 20 insertion mutations showed promising preliminary anti-tumor activity and an acceptable safety profile across all of the doses tested in a phase 1 trial of CLN-081.

Pralsentinib Demonstrates Tolerability and Elicits Durable Responses in RET Fusion-Positive NSCLC

June 04, 2021

In the phase 1/2 ARROW study, pralsentinib was found to be well-tolerated and showed durable responses as treatment of patients with RET fusion-positive non-small cell lung cancer, including those who were not eligible for platinum-based therapy.

FDA Approves Guardant360 Liquid Biopsy as CDx for Sotorasib in NSCLC

June 01, 2021

The FDA has approved Guardant360, a liquid biopsy companion diagnostic for tumor mutation profiling or comprehensive genomic profiling to identify patients with locally advanced or metastatic non-small cell lung cancer who have a KRAS G12C mutation and may benefit from sotorasib.

FDA Approves Sotorasib for KRAS G12C+ Locally Advanced or Metastatic NSCLC

May 28, 2021

The FDA has granted accelerated approval to sotorasib for the treatment of adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer, as determined by an FDA-approved test, who have received at least one prior systemic therapy.